Zhao Wen-Zhuo, Wang Hong-Gang, Yang Xiao-Zhong
Department of Gastroenterology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an 223300, Jiangsu Province, China.
World J Gastroenterol. 2024 Jan 28;30(4):421-423. doi: 10.3748/wjg.v30.i4.421.
According to the latest global cancer statistics, colorectal cancer (CRC) has emerged as the third most prevalent malignant tumor across the globe. In recent decades, the medical field has implemented several levels of CRC screening tests, encompassing fecal tests, endoscopic examinations, radiological examinations and blood tests. Previous studies have shown that leukocyte immunoglobulin-like receptor B2 (LILRB2) is involved in inhibiting immune cell function, immune evasion, and promoting tumor progression in acute myeloid leukemia and non-small cell lung cancer. However, its interaction with CRC has not been reported yet. Recently, a study published in the revealed that LILRB2 and its ligand, angiopoietin-like protein 2, are markedly overexpressed in CRC. This overexpression is closely linked to tumor progression and is indicative of a poor prognosis. The study highlights the potential of utilizing the concentration of LILRB2 in serum as a promising biomarker for tumors. However, there is still room for discussion regarding the data processing and analysis in this research.
根据最新的全球癌症统计数据，结直肠癌（CRC）已成为全球第三大常见恶性肿瘤。近几十年来，医学领域实施了多个层面的CRC筛查测试，包括粪便检测、内镜检查、放射检查和血液检测。先前的研究表明，白细胞免疫球蛋白样受体B2（LILRB2）参与抑制免疫细胞功能、免疫逃逸，并促进急性髓系白血病和非小细胞肺癌的肿瘤进展。然而，其与CRC的相互作用尚未见报道。最近，发表在《 》上的一项研究表明，LILRB2及其配体血管生成素样蛋白2在CRC中明显过表达。这种过表达与肿瘤进展密切相关，预示着预后不良。该研究突出了将血清中LILRB2的浓度作为一种有前景的肿瘤生物标志物的潜力。然而，这项研究中的数据处理和分析仍有讨论空间。
